With the second half of the year underway, Oppenheimer is highlighting what it calls its top small- and midcap seasonal standout investment ideas. Smallcap stocks have underperformed the S & P 500 this year, with the Russell 2000 virtually unchanged, up a scant 0.12% through Tuesday. The broad market index, however, has advanced around 17%. Midcaps haven't done much better, with the S & P 400 MidCap higher by only 3.8% in 2024.
mountain Viking Therapeutics, year-to-date Oppenheimer's bullish view of Viking rests on a possible "best-in-class profile" for both the oral dosage and subcutaneous injection of the company's GLP-1 and GIP dual agonists VK2735.
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite: